
Roflast500 mcg
Beacon Pharmaceuticals PLC
Roflumilast is indicated as a treatment to reduce the risk of exacerbations (flare-ups) in adults with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis who have…
Roflumilast is indicated as a treatment to reduce the risk of exacerbations (flare-ups) in adults with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis who have a history of frequent exacerbations.
Use of Roflumilast for any other condition should only be considered under specific physician guidance, as this is not an approved indication for this oral formulation.
Dosing of Roflumilast by indication and population:
| Population / Indication | Recommended Dose |
|---|---|
| Adults – severe COPD with chronic bronchitis and a history of exacerbations | Roflumilast 500 microgram (mcg) orally, once daily, long-term, as an add-on to bronchodilator therapy |
| Mild hepatic impairment (Child-Pugh A) | No dose adjustment required; use with caution |
| Moderate-to-severe hepatic impairment (Child-Pugh B or C) | Contraindicated — see Contraindications |
| Renal impairment | No dose adjustment required |
| Elderly patients | No dose adjustment required; monitor as for general adult population |
| Pediatric patients (under 18 years) | Safety and efficacy not established; not recommended |
Tablets should be swallowed whole with water, with or without food, at approximately the same time each day. Full clinical benefit in reducing exacerbations may take several weeks to months of continuous therapy to become apparent; do not stop treatment abruptly without consulting a physician.
The most commonly reported side effects of Roflumilast include:
Psychiatric effects such as anxiety, depression, and — rarely — suicidal thoughts or behavior have been reported (see Precautions and Warnings). Gastrointestinal side effects tend to occur early in treatment and often diminish over time; however, any persistent or severe symptoms, mood changes, or significant unintentional weight loss should be reported to a physician promptly.
Roflumilast is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.